The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ACLX | -12.72% | N/A | N/A | +415% |
| S&P | +12.65% | +91.73% | +13.89% | +50% |
Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $4.95M | -81.0% |
| Gross Profit | $3.11M | -87.4% |
| Gross Margin | 62.76% | -32.1% |
| Market Cap | $4.55B | 1.4% |
| Market Cap / Employee | $27.93M | 0.0% |
| Employees | 163 | 25.4% |
| Net Income | -$55.78M | -115.6% |
| EBITDA | -$59.93M | -85.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $79.01M | -51.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $44.32M | -6.1% |
| Short Term Debt | $7.47M | -58.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -30.67% | -24.8% |
| Return On Invested Capital | -45.91% | 5.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$49.50M | -274.1% |
| Operating Free Cash Flow | -$49.21M | -260.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 8.57 | 7.83 | 8.70 | 11.59 | 26.07% |
| Price to Sales | 38.58 | 47.19 | 64.97 | 129.42 | 348.65% |
| Price to Tangible Book Value | 8.57 | 7.83 | 8.70 | 11.59 | 26.07% |
| Price to Free Cash Flow TTM | 15.59 | 1254.44 | - | ||
| Enterprise Value to EBITDA | -70.68 | -46.56 | -57.81 | -70.68 | -42.75% |
| Free Cash Flow Yield | 6.4% | 0.1% | - | ||
| Return on Equity | -22.8% | -35.6% | -42.8% | -47.2% | 337.15% |
| Total Debt | $54.08M | $53.19M | $52.51M | $51.79M | -20.72% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
